Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nanoparticle tumour vaccines

A nanoparticle, vaccine technology, applied in the field of nanoparticle-mediated delivery, which can solve the problems of discomfort and human use, high toxicity, etc.

Inactive Publication Date: 2014-07-30
MIDATECH LTD +1
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many adjuvants are considered too toxic for discomfort and human use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanoparticle tumour vaccines
  • Nanoparticle tumour vaccines
  • Nanoparticle tumour vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0142] Example 1 - Synthesis and Characterization of Nanoparticles

[0143] The test ligands and their identification numbers are given below (molecule wt);

[0144] SIINFEKL (963) (SEQ ID NO: 87)

[0145] SIINFEKL-N-(CH 2 ) 2 -SH (1021)

[0146] FLSIINFEKL-N-(CH 2 ) 2 -SH (1280) (SEQ ID NO: 88)

[0147] FLAAYSIINFEKL-N-(CH 2 ) 2 -SH (1587) (SEQ ID NO: 89)

[0148] AAYSIINFEKL-N-(CH 2 ) 2 -SH (1325) (SEQ ID NO:90)

[0149] HS(CH 2 ) 2 -CONH-SIINFEKL (1051)

[0150] HS(CH 2 ) 2 -CONH-FLSIINFEKL (1309)

[0151] HS(CH 2 ) 2 -CONH-FLAAYSIINFEKL (1616)

[0152] HS(CH 2 ) 2 -CONH-AAYSIINFEKL (1356)

[0153] HS-(CH 2 ) 10 -(CH 2 OCH 2 ) 7 -CONH-SIINFEKL (1471)

[0154] HS-(CH 2 ) 10 -(CH 2 OCH 2 ) 7 -CONH-FLSIINFEKL (1732)

[0155] HS-(CH 2 ) 10 -(CH 2 OCH 2 ) 7 -CONH-FLAAYSIINFEKL (2034)

[0156] HS-(CH 2 ) 10 -(CH 2 OCH 2 ) 7 -CONH-AAYSIINFEKL (1774)

[0157] Test NPs were synthesized using 10 μmole of gold chloride (Aldrich484385), 30...

Embodiment 2

[0193] Example 2 - Evaluation of Presentation Assays

[0194] The T cell receptor (TCR) is on the surface of T lymphocytes and recognizes peptides in the context of the major histocompatibility complex (MHC) (1). In general, antigen-presenting cells (APCs) contain machinery to process proteins and load them onto empty MHC. While CD4+ T cells recognize MHC class II (MHC II), CD8+ T cells respond to MHC class I (MHC I). Previously, MHCII peptides were derived from endocytic components of the extracellular milieu. In contrast, MHCI is loaded with processed peptides from cellular endogenous sources (1,2).

[0195] SIINFEKL (SEQ ID NO: 87), is a peptide epitope from ovalbumin (OVA) in a protein called H-2K b are presented in the context of the murine MHCI allele (3). If OVA is expressing H-2K b SIINFEKL (SEQ ID NO: 87) is routinely presented in mouse cells. However, if OVA is provided exogenously, SIINFEKL can be presented by an alternative method called MHCI cross-presentati...

Embodiment 3

[0223] Example 3 - Nanoparticle-peptide presentation assay

[0224] The test ligands listed below were constructed and chemically attached to gold nanoparticles (GNPs) via the linkers described above.

[0225] 1. SIINFEKL (SEQ ID NO: 87)

[0226] 2. SIINFEKL-N-(CH2)2-SH

[0227] 3. FLSIINFEKL-N-(CH2)2-SH (SEQ ID NO: 88)

[0228] 4. FLAAYSIINFEKL-N-(CH2)2-SH (SEQ ID NO: 89)

[0229] 5. AAYSIINFEKL-N-(CH2)2-SH (SEQ ID NO:90)

[0230] 6. HS(CH2)2-CONH-SIINFEKL

[0231] 7. HS(CH2)2-CONH-FLSIINFEKL

[0232] 8. HS(CH2)2-CONH-FLAAYSIINFEKL

[0233] 9. HS(CH2)2-CONH-AAYSIINFEKL

[0234] 10.HS-(CH2)10-(CH2OCH2)7-CONH-SIINFEKL

[0235] 11.HS-(CH2)10-(CH2OCH2)7-CONH-FLSIINFEKL

[0236] 12.HS-(CH2)10-(CH2OCH2)7-CONH-FLAAYSIINFEKL

[0237] 13.HS-(CH2)10-(CH2OCH2)7-CONH-AAYSIINFEKL

[0238] SIINFEKL (SEQ ID NO: 87) is an epitope from ovalbumin that is presented in the context of the murine MHC I molecule H-2Kb and measured using two methods. One approach utilizes a TCR-like anti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention provides a vaccine for the prophylactic or therapeutic treatment of a tumour in a mammalian subject, as well as methods of using the vaccine, including in treatment of tumours and in generating a CTL response. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier, salt or diluent. The nanoparticles comprise a core comprising a metal and / or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that iscovalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises an epitopic peptide that is covalently linked to the core via a second linker, said second linker comprising a peptide portion and a non-peptide portion, wherein said peptide portion comprises the sequence X1X2Z1, wherein: X1 is an amino acid selected from A and G; X2 is an amino acid selected from A and G; and Z1 is an amino acid selected from Y and F, and wherein said epitopic peptide forms at least a portion of or is derived from a Tumour-Associated Antigen (TAA).

Description

field of invention [0001] The present invention relates to substances and compositions for use in peptide-based vaccine regimens, in particular nanoparticle-mediated delivery of peptides for stimulating T cell responses. Vaccine regimens are directed towards the therapeutic and prophylactic treatment of tumors such as lung cancer tumors. Background of the invention [0002] Cytotoxic T lymphocytes (CTLs) are specialized T cells that function primarily by recognizing and killing cancer or infected cells, but also by secreting proteins called cytokines that mediate a variety of effects on the immune system The soluble molecules function. Evidence suggests that immunotherapy aimed at stimulating tumor-specific CTL responses will effectively control cancer. For example, human CTLs have been shown to recognize sarcoma (Slovin, S.F. et al., J. Immunol., 137:3042-3048, (1987)), renal cell carcinoma (Schendel, D.J. et al., J. Immunol., 151: 4209-4220, (1993)), colorectal cancer (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61P35/00
CPCA61K47/6923A61K47/6929A61P35/00A61P37/04A61K39/0011A61K2039/86A61K47/50A61K9/16A61K9/141
Inventor T·雷德梅彻尔R·菲利普
Owner MIDATECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com